Cytek Biosciences
CTKB
136 hedge funds and large institutions have $415M invested in Cytek Biosciences in 2024 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 67 increasing their positions, 32 reducing their positions, and 12 closing their positions.
109% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 32
58% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 12
5% more funds holding
Funds holding: 129 → 136 (+7)
2% less capital invested
Capital invested by funds: $425M → $415M (-$9.85M)
1.04% less ownership
Funds ownership: 58.04% → 57% (-1%)
60% less call options, than puts
Call options by funds: $2K | Put options by funds: $5K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$8.06M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.21M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.1M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.04M |
| 5 |
Morgan Stanley
New York
|
+$979K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
-$10.7M |
| 2 |
New York State Common Retirement Fund
Albany,
New York
|
-$4.88M |
| 3 |
Millennium Management
New York
|
-$4.29M |
| 4 |
Goldman Sachs
New York
|
-$1.9M |
| 5 |
DM
Deerfield Management
New York
|
-$784K |
CTKB Hedge Fund Activity: Q3 2024 in Review
136 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Cytek Biosciences (CTKB) for Q3 2024, worth a combined $415M — down 2.3% from $425M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new CTKB positions and 12 closed out — a net gain of 7 holders — while 67 added to existing stakes and 32 trimmed.
The largest buyer was BlackRock, adding an estimated $8.06M. The largest seller was Brown Capital Management, cutting an estimated $10.7M.
- 136 institutional investors held Cytek Biosciences (CTKB) as of Q3 2024, up from 129 in Q2 2024.
- Funds reported $415M of Cytek Biosciences stock for Q3 2024, down 2.3% quarter-over-quarter.
- 19 funds opened new Cytek Biosciences positions in Q3 2024 and 12 closed out, a net change of +7 holders.
- The largest Cytek Biosciences buyer in Q3 2024 was BlackRock, an estimated $8.06M added.
- The largest Cytek Biosciences seller in Q3 2024 was Brown Capital Management, an estimated $10.7M sold.
Based on aggregated 13F filings for Q3 2024.